vs
VERACYTE, INC.（VCYT）与WSFS FINANCIAL CORP（WSFS）财务数据对比。点击上方公司名可切换其他公司
WSFS FINANCIAL CORP的季度营收约是VERACYTE, INC.的2.0倍（$275.3M vs $140.6M），WSFS FINANCIAL CORP净利率更高（31.5% vs 29.3%，领先2.3%），VERACYTE, INC.同比增速更快（18.5% vs 7.5%），过去两年VERACYTE, INC.的营收复合增速更高（20.5% vs 1.7%）
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
WSFS金融集团是一家金融服务企业，核心子公司WSFS银行是总部位于特拉华州及大特拉华谷地区规模最大、经营历史最久的本地管理银行与财富管理机构。集团共运营115个网点，其中88个为银行网点，分布在宾夕法尼亚、特拉华、新泽西、佛罗里达、弗吉尼亚、内华达六州，提供全面金融服务。
VCYT vs WSFS — 直观对比
营收规模更大
WSFS
是对方的2.0倍
$140.6M
营收增速更快
VCYT
高出11.1%
7.5%
净利率更高
WSFS
高出2.3%
29.3%
两年增速更快
VCYT
近两年复合增速
1.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $140.6M | $275.3M |
| 净利润 | $41.1M | $86.8M |
| 毛利率 | 72.5% | — |
| 营业利润率 | 26.4% | — |
| 净利率 | 29.3% | 31.5% |
| 营收同比 | 18.5% | 7.5% |
| 净利润同比 | 704.8% | 31.7% |
| 每股收益（稀释后） | $0.50 | $1.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收VCYTWSFS
| Q1 26 | — | $275.3M | ||
| Q4 25 | $140.6M | $271.9M | ||
| Q3 25 | $131.9M | $270.5M | ||
| Q2 25 | $130.2M | $267.5M | ||
| Q1 25 | $114.5M | $256.1M | ||
| Q4 24 | $118.6M | $261.5M | ||
| Q3 24 | $115.9M | $267.7M | ||
| Q2 24 | $114.4M | $266.0M |
净利润VCYTWSFS
| Q1 26 | — | $86.8M | ||
| Q4 25 | $41.1M | $72.7M | ||
| Q3 25 | $19.1M | $76.4M | ||
| Q2 25 | $-980.0K | $72.3M | ||
| Q1 25 | $7.0M | $65.9M | ||
| Q4 24 | $5.1M | $64.2M | ||
| Q3 24 | $15.2M | $64.4M | ||
| Q2 24 | $5.7M | $69.3M |
毛利率VCYTWSFS
| Q1 26 | — | — | ||
| Q4 25 | 72.5% | — | ||
| Q3 25 | 69.2% | — | ||
| Q2 25 | 69.0% | — | ||
| Q1 25 | 69.5% | — | ||
| Q4 24 | 66.4% | — | ||
| Q3 24 | 68.2% | — | ||
| Q2 24 | 68.1% | — |
营业利润率VCYTWSFS
| Q1 26 | — | — | ||
| Q4 25 | 26.4% | 35.8% | ||
| Q3 25 | 17.4% | 37.3% | ||
| Q2 25 | -4.0% | 35.7% | ||
| Q1 25 | 2.5% | 34.0% | ||
| Q4 24 | 3.5% | 32.3% | ||
| Q3 24 | 10.4% | 31.9% | ||
| Q2 24 | 4.0% | 34.0% |
净利率VCYTWSFS
| Q1 26 | — | 31.5% | ||
| Q4 25 | 29.3% | 26.7% | ||
| Q3 25 | 14.5% | 28.3% | ||
| Q2 25 | -0.8% | 27.0% | ||
| Q1 25 | 6.2% | 25.7% | ||
| Q4 24 | 4.3% | 24.6% | ||
| Q3 24 | 13.1% | 24.1% | ||
| Q2 24 | 5.0% | 26.0% |
每股收益（稀释后）VCYTWSFS
| Q1 26 | — | $1.64 | ||
| Q4 25 | $0.50 | $1.33 | ||
| Q3 25 | $0.24 | $1.37 | ||
| Q2 25 | $-0.01 | $1.27 | ||
| Q1 25 | $0.09 | $1.12 | ||
| Q4 24 | $0.07 | $1.08 | ||
| Q3 24 | $0.19 | $1.08 | ||
| Q2 24 | $0.07 | $1.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $362.6M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $2.7B |
| 总资产 | $1.4B | $22.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资VCYTWSFS
| Q1 26 | — | — | ||
| Q4 25 | $362.6M | $1.7B | ||
| Q3 25 | $315.6M | — | ||
| Q2 25 | $219.5M | — | ||
| Q1 25 | $186.1M | — | ||
| Q4 24 | $239.1M | $1.2B | ||
| Q3 24 | $274.1M | — | ||
| Q2 24 | $235.9M | — |
股东权益VCYTWSFS
| Q1 26 | — | $2.7B | ||
| Q4 25 | $1.3B | $2.7B | ||
| Q3 25 | $1.3B | $2.8B | ||
| Q2 25 | $1.2B | $2.7B | ||
| Q1 25 | $1.2B | $2.7B | ||
| Q4 24 | $1.2B | $2.6B | ||
| Q3 24 | $1.2B | $2.7B | ||
| Q2 24 | $1.1B | $2.5B |
总资产VCYTWSFS
| Q1 26 | — | $22.1B | ||
| Q4 25 | $1.4B | $21.3B | ||
| Q3 25 | $1.4B | $20.8B | ||
| Q2 25 | $1.3B | $20.8B | ||
| Q1 25 | $1.3B | $20.5B | ||
| Q4 24 | $1.3B | $20.8B | ||
| Q3 24 | $1.3B | $20.9B | ||
| Q2 24 | $1.2B | $20.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $52.6M | — |
| 自由现金流经营现金流 - 资本支出 | $48.8M | — |
| 自由现金流率自由现金流/营收 | 34.7% | — |
| 资本支出强度资本支出/营收 | 2.7% | — |
| 现金转化率经营现金流/净利润 | 1.28× | — |
| 过去12个月自由现金流最近4个季度 | $126.6M | — |
8季度趋势，按日历期对齐
经营现金流VCYTWSFS
| Q1 26 | — | — | ||
| Q4 25 | $52.6M | $220.0M | ||
| Q3 25 | $44.8M | $121.5M | ||
| Q2 25 | $33.6M | $37.2M | ||
| Q1 25 | $5.4M | $8.7M | ||
| Q4 24 | $24.5M | $219.9M | ||
| Q3 24 | $30.0M | $3.1M | ||
| Q2 24 | $29.6M | $44.8M |
自由现金流VCYTWSFS
| Q1 26 | — | — | ||
| Q4 25 | $48.8M | $213.6M | ||
| Q3 25 | $42.0M | $120.3M | ||
| Q2 25 | $32.3M | $35.2M | ||
| Q1 25 | $3.5M | $6.3M | ||
| Q4 24 | $20.4M | $205.6M | ||
| Q3 24 | $27.7M | $-489.0K | ||
| Q2 24 | $26.8M | $42.1M |
自由现金流率VCYTWSFS
| Q1 26 | — | — | ||
| Q4 25 | 34.7% | 78.6% | ||
| Q3 25 | 31.8% | 44.5% | ||
| Q2 25 | 24.8% | 13.2% | ||
| Q1 25 | 3.1% | 2.5% | ||
| Q4 24 | 17.2% | 78.6% | ||
| Q3 24 | 23.9% | -0.2% | ||
| Q2 24 | 23.4% | 15.8% |
资本支出强度VCYTWSFS
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | 2.3% | ||
| Q3 25 | 2.1% | 0.5% | ||
| Q2 25 | 1.0% | 0.7% | ||
| Q1 25 | 1.6% | 0.9% | ||
| Q4 24 | 3.5% | 5.5% | ||
| Q3 24 | 1.9% | 1.4% | ||
| Q2 24 | 2.4% | 1.0% |
现金转化率VCYTWSFS
| Q1 26 | — | — | ||
| Q4 25 | 1.28× | 3.03× | ||
| Q3 25 | 2.34× | 1.59× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | 0.76× | 0.13× | ||
| Q4 24 | 4.80× | 3.43× | ||
| Q3 24 | 1.98× | 0.05× | ||
| Q2 24 | 5.16× | 0.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
WSFS
暂无分部数据
